Egrifta (Tesamorelin) Nicotine Interaction Profile

Does the Egrifta label list nicotine as an interaction?

No. Section 7 of both labels has two entries: drugs metabolized by CYP450 enzymes, where the label says to monitor for potential interactions, and glucocorticoids [1][2]. Nicotine, cigarettes, vaping and nicotine replacement therapy are not named there. Nicotine also does not appear among the contraindications, which are hypothalamic-pituitary axis disruption, active malignancy, hypersensitivity to tesamorelin or its excipients, and pregnancy [1].

The glucocorticoid entry is often misread. The label does not say steroids blunt tesamorelin. It says growth hormone inhibits 11-beta-hydroxysteroid dehydrogenase type 1, the enzyme that converts cortisone and prednisone into their active forms, so people taking glucocorticoid replacement for hypoadrenalism may need higher maintenance or stress doses after starting tesamorelin [1].

What cigarette smoke does that nicotine does not

Cigarette smoke induces the liver enzyme CYP1A2, and polycyclic aromatic hydrocarbons in the smoke are believed to be responsible [5]. Nicotine itself is not the inducer: a review of drugs affected by quitting states that the effect on hepatic microsomal enzymes is not related to the nicotine component of tobacco, so nicotine replacement will not alter it [3].

That induction matters for drugs the enzyme clears, such as caffeine, clozapine and theophylline [5]. The Egrifta labels do not name tesamorelin as a CYP1A2 substrate and report no formal human metabolism studies. Tesamorelin's elimination half-life is about 8 minutes (Egrifta SV 1.4 mg, healthy subjects) [1].

Nicotine itself causes peripheral vasoconstriction, a faster heart rate and higher blood pressure, and tolerance does not develop to its catecholamine-releasing effects [4].

What the labels do ask you to watch

IGF-1: tesamorelin stimulates growth hormone production and raises IGF-1, and the effects of prolonged elevation are unknown. The label says to monitor IGF-1 and to consider discontinuing in patients with persistent elevations (for example above 3 SDS), particularly when the fat-loss response is not robust [1]. Among patients treated for 26 weeks, 47% had IGF-1 above 2 SDS and 36% above 3 SDS; among those treated for 52 weeks, 34% and 23% [1].

Glucose: an HbA1c of 6.5% or higher developed in 5% of tesamorelin patients versus 1% on placebo by week 26, a hazard ratio of about 3.3 (95% CI 1.4 to 9.6) [1].